Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Driven by a cyclical rebound across overweight life sciences tools holdings, while initiating turnaround stakes in Biogen and Humana and exiting 14 positions.
Full Quick Take
Driven by a cyclical rebound across overweight life sciences tools holdings, while initiating turnaround stakes in Biogen and Humana and exiting 14 positions.
The Fund experienced subpar relative performance in Q2 2025 due to a momentum-driven market rally that favored growth over value, but managers remain confident in their high-conviction, concentrated portfolio.
Full Quick Take
The Fund experienced subpar relative performance in Q2 2025 due to a momentum-driven market rally that favored growth over value, but managers remain confident in their high-conviction, concentrated portfolio.